Malgorzata Gajda, MD
Internal Medicine · Oak Lawn, ILNPI 1548285042
Payments from drug & device makers
Across 568 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$1K
- Pfizer$1K
- GSK$998
- Boehringer Ingelheim$982
- plus $5K from 29 others
What the payments were for
- Consulting fees$1,2009%
- Food & beverage$11,61890%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 86 | $1,883 |
| Biohaven Pharmaceuticals, Inc. | 6 | $1,296 |
| AbbVie(2 entities) | 64 | $1,269 |
| Pfizer | 58 | $1,242 |
| GSK | 56 | $998 |
| Boehringer Ingelheim | 38 | $982 |
| AstraZeneca | 45 | $947 |
| Lilly USA, LLC | 39 | $714 |
| Amgen | 43 | $619 |
| Otsuka America Pharmaceutical, Inc. | 20 | $470 |
| Sanofi-aventis U.S. LLC | 16 | $289 |
| Johnson & Johnson | 15 | $278 |
| Novartis | 14 | $273 |
| Madrigal Pharmaceuticals | 5 | $217 |
| Astellas Pharma US Inc | 11 | $211 |
| Bayer | 7 | $163 |
| Amarin Pharma, Inc. | 8 | $129 |
| E.r. Squibb & Sons, L.L.C. | 3 | $124 |
| Abbott | 5 | $114 |
| Tactile Systems Technology Inc | 1 | $98 |
| Teva Pharmaceuticals USA, Inc. | 5 | $93 |
| Exact Sciences | 4 | $86 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $45 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Merck | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Ironwood Pharmaceuticals, Inc | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Shield Therapeutics Inc | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Exeltis, USA Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- ELIQUIS$268
- REZDIFFRA$142
- Ozempic$122
How this compares
$12,854 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $91,049 |
| EliquisApixaban | 36 | $49,346 |
| FarxigaDapagliflozin Propanediol | 36 | $39,634 |
| XareltoRivaroxaban | 13 | $16,963 |
| MounjaroTirzepatide | 16 | $16,107 |
| JanuviaSitagliptin Phosphate | 18 | $15,074 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $10,124 |
| Repatha SyringeEvolocumab | 12 | $6,775 |
| Rosuvastatin Calcium | 320 | $5,356 |
| Esomeprazole Magnesium | 14 | $2,880 |
| Metoprolol Succinate | 134 | $2,768 |
| Amlodipine Besylate | 328 | $2,642 |
| Levothyroxine Sodium | 215 | $2,615 |
| Atorvastatin Calcium | 200 | $2,517 |
| Pregabalin | 13 | $1,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,883 | $91,04949 claims |
| PfizerEliquis | $1,242 | $49,34636 claims |
| AstraZenecaFarxiga | $947 | $39,63436 claims |
| Johnson & JohnsonXarelto | $278 | $16,96313 claims |
| Lilly USA, LLCMounjaro | $714 | $16,10716 claims |
| MerckJanuvia | $39 | $15,07418 claims |
| AbbVieSynthroid | $1,269 | $1,64425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Oak Lawn
- William CruikshankOak Lawn$431K
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.